Elypta is a pioneering brand on a mission to prevent cancer mortality through early detection. They have developed a groundbreaking metabolism-based liquid biopsy, known as the Elypta MIRAM® Kit, which allows for noninvasive detection of cancer. By measuring the GAGome, which are system biomarkers of tumor metabolism, Elypta uses machine learning to detect signatures of cancer.

Their innovative approach has already shown a double multi-cancer detection rate in the earliest stages of cancer. Elypta is committed to advancing cancer detection and is actively involved in clinical studies and research. They have received ISO 13485:2016 Quality System Certification and have been awarded the prestigious $1 million Grand Prize from the Roddenberry Foundation.

Additionally, Elypta has secured $21 million in Series A funding to develop their metabolism-based multi-cancer early detection test. Elypta invites collaborations with academia and industry for the development of companion diagnostics and welcomes interest from investors. They are also open to top talents joining their development team.

Located in Solna, Sweden, Elypta is at the forefront of revolutionizing cancer detection through innovative science and cutting-edge technology